Bioventus Surges 103% in Six Months: Is the Stock Worth a Buy? [Yahoo! Finance]
Bioventus Inc. - Class A (BVS)
Company Research
Source: Yahoo! Finance
This upside can be attributed to the encouraging sales performance across its business segments, based on which management raised the 2024 guidance twice this year. In the past six months, BVS stock significantly outperformed the industry's 5.1% rise. The stock has also outperformed the sector and the S&P 500 during the same period. BVS shares are also trading above the 50-day and 200-day moving averages. BVS Stock Outperforms Industry, Sector & S&P 500 Image Source: Zacks Investment Research BVS Boasts Accelerated Topline Growth Bioventus focuses on making minimally invasive treatments that engage and enhance the body's natural healing process. Its business is divided into three segments — Pain Treatments, Restorative Therapies and Surgical Solutions. The company is seeing double-digit revenue growth in both the Pain Treatments and Surgical Solutions segments, driven by the strong commercial execution of its sales force. Organic sales rosenearly 14% year over year in seco
Show less
Read more
Impact Snapshot
Event Time:
BVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BVS alerts
High impacting Bioventus Inc. - Class A news events
Weekly update
A roundup of the hottest topics
BVS
News
- Pressure Ulcers Treatment Markets, 2024-2028 & 2033 [Yahoo! Finance]Yahoo! Finance
- Bioventus Inc. (NYSE: BVS) had its price target raised by analysts at Canaccord Genuity Group Inc. from $12.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
- Bioventus Inc (BVS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ... [Yahoo! Finance]Yahoo! Finance
- Bioventus (BVS) Matches Q3 Earnings Estimates [Yahoo! Finance]Yahoo! Finance
- Bioventus: Q3 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
BVS
Earnings
- 11/5/24 - In-Line
BVS
Sec Filings
- 11/14/24 - Form SCHEDULE
- 11/8/24 - Form SC
- 11/5/24 - Form 10-Q
- BVS's page on the SEC website